<SEC-DOCUMENT>0001144204-19-047242.txt : 20191004
<SEC-HEADER>0001144204-19-047242.hdr.sgml : 20191004
<ACCEPTANCE-DATETIME>20191004060428
ACCESSION NUMBER:		0001144204-19-047242
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190930
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191004
DATE AS OF CHANGE:		20191004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		191137570

	BUSINESS ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801
		BUSINESS PHONE:		(626) 282-0288

	MAIL ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv530664_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM
8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT
TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (date
of earliest event reported): September 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>APOLLO
MEDICAL HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant
as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 179.15pt 0pt 180.5pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 34%; padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">001-37392</FONT></TD>
    <TD STYLE="width: 33%; padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">95-4472349</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">(State or Other Jurisdiction</FONT></TD>
    <TD STYLE="padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File</FONT></TD>
    <TD STYLE="padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">of Incorporation)</FONT></TD>
    <TD STYLE="padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">Number)</FONT></TD>
    <TD STYLE="padding: 0; text-align: center"><FONT STYLE="font-size: 10pt">Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 179.15pt 0pt 180.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 175pt 0pt 175.75pt; text-align: center">1668 S. Garfield Avenue,
2nd Floor, Alhambra, CA 91801</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 175pt 0pt 175.75pt; text-align: center">(Address of principal executive
offices) (zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 175.6pt 0pt 176.95pt; text-align: center">(626) 282-0288</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 175.6pt 0pt 176.95pt; text-align: center">(Registrant&rsquo;s telephone
number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 274pt 0pt 274.75pt; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 160.75pt 0pt 162.1pt; text-align: center">(Former name or former
address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Precommencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Precommencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Emerging growth company <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of
the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 34%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">AMEH</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">Nasdaq Capital Market</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 5.02</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>(c)</B></TD><TD STYLE="text-align: justify"><B>Appointment of Officers</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.5pt 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.5pt 0pt 0; text-indent: 0.5in">On September 30, 2019, upon the
recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the &ldquo;Board&rdquo;) of Apollo
Medical Holdings, Inc. (the &ldquo;Company&rdquo;), the Board appointed (i) Kenneth Sim, M.D. to serve as Co-Chief Executive Officer
of the Company, and (ii) Thomas Lam, M.D. to serve as President of the Company to fill the vacant position following Gary Augusta&rsquo;s
termination. In addition to such appointments, Dr. Sim will continue to serve as the Company&rsquo;s Executive Chairman, and Dr.
Lam will continue to serve as its Co-Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.5pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>(e)</B></TD><TD STYLE="text-align: justify"><B>Compensatory Arrangements of Certain Officers</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.5pt 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.5pt 0pt 0; text-indent: 0.5in">On September 30, 2019, upon the
recommendation of the Compensation Committee of the Board, the Board approved the payment by the Company to Kenneth Sim, M.D. and
Thomas Lam, M.D. of cash bonuses and the grant by the Company to each of them of restricted shares of the Company&rsquo;s common
stock and non-qualified stock options to purchase the Company&rsquo;s common stock, as set forth in the table below. In furtherance
thereof, Dr. Sim and Dr. Lam have each entered into a Restricted Stock Agreement and a Stock Option Agreement with the Company,
as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.5pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.5pt 0pt 0; text-indent: 0.5in">For each of Dr. Sim and Dr. Lam,
the restricted shares of common stock were granted under the Company&rsquo;s 2015 Equity Incentive Plan (the &ldquo;2015 Plan&rdquo;),
subject to vesting one-third after year one (on September 30, 2020), one-third after year two (on September 30, 2021), and the
final one-third after year three (on September 30, 2022). In addition, for each of Dr. Sim and Dr. Lam, the options to purchase
the Company&rsquo;s common stock were granted under the 2015 Plan, which options will vest and become exercisable one-third after
year one (on September 30, 2020), one-third after year two (on September 30, 2021), and the final one-third after year three (on
September 30, 2022), subject to expiration on the date that is five years from the date of grant (i.e., on September 30, 2024).
The exercise price for each share subject to the stock options granted is $17.62, the closing price of the Company&rsquo;s common
stock on the date of grant (i.e., September 30, 2019).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.5pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.5pt 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Grantee</TD><TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Cash Bonus</TD><TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Restricted Stock Grant</TD><TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Stock Option Grant</TD><TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 43%; font-size: 10pt; text-align: left">Kenneth Sim, M.D.</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">100,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">58,883</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">39,189</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Executive Chairman and Co-Chief Executive Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Thomas Lam, M.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">100,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">58,883</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">39,189</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">President and Co-Chief Executive Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.5pt 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 8.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Other Events.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-indent: 0.5in">On October 2, 2019, the Company
issued a Press Release announcing that it has entered into a new Management Services Agreement (&ldquo;MSA&rdquo;), effective January
1, 2020, to provide management services, via a subcontract agreement, to an independent practice association (&ldquo;IPA group&rdquo;).
The IPA group currently serves approximately 145,000 members in three main markets within Southern California; South Los Angeles,
San Fernando Valley, and Antelope Valley. The majority of the members are enrolled in Medi-Cal, with members also enrolled in Medicare
Advantage and Commercial health plans, and are supported by a network of hundreds of primary care physicians and nearly a thousand
specialists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-indent: 0.5in">A copy of the Press Release is
provided as Exhibit 99.1 to this Current Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements
and Exhibits.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
    <TD STYLE="width: 2%; padding: 0 0 1pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 88%; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv530664_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv530664_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release of Apollo Medical Holdings, Inc., dated October 2, 2019.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 250.15pt 0pt 251.45pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 250.15pt 0pt 251.45pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-indent: 0.5in">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>APOLLO MEDICAL HOLDINGS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Dated: October 4, 2019</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By: &nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas S. Lam, M.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Thomas S. Lam, M.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Co-Chief Executive Office</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 294.9pt">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 530pt 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv530664_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 87.75pt; width: 253.5pt"><BR>
 &nbsp; <B>APOLLO MEDICAL HOLDINGS ADDS APPROXIMATELY 145,000 MEMBERS BY ENTERING INTO NEW MANAGEMENT SERVICES AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Alhambra, CA &ndash; (PR Newswire)
 &ndash; October 2, 2019 &ndash;</I></B> Apollo Medical Holdings, Inc. (&ldquo;ApolloMed&rdquo; or the &ldquo;Company&rdquo;) (NASDAQ:
AMEH), an integrated population health management company, today announced that it has entered into a new Management Services Agreement
(&ldquo;MSA&rdquo;), effective January 1, 2020, to provide management services, via a subcontract agreement, to an independent
practice association (&ldquo;IPA group&rdquo;). The IPA group currently serves approximately 145,000 members in three main markets
within Southern California; South Los Angeles, San Fernando Valley, and Antelope Valley. The majority of the members are enrolled
in Medi-Cal, with members also enrolled in Medicare Advantage and Commercial health plans, and are supported by a network of hundreds
of primary care physicians and nearly a thousand specialists to provide exceptional care for its members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This agreement significantly bolsters
the number of members under our management and expands our reach into new communities within Southern California and providing
growth in our management services platform. Consistent with our strategic plan, this agreement also brings the opportunity to further
scale our business model and realize additional efficiencies,&rdquo; said Kenneth Sim, M.D., Executive Chairman and Co-Chief Executive
Officer of ApolloMed. &ldquo;We are in excellent position to support the financial goals and enable organizational success of the
IPA group for years to come,&rdquo; stated Dr. Kenneth Sim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Apollo Medical Holdings, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">ApolloMed is a
leading physician-centric integrated population health management company, which, together with its subsidiaries, including a Next
Generation Accountable Care Organization (&ldquo;NGACO&rdquo;), and its affiliated IPAs and management services organizations (&ldquo;MSOs&rdquo;),
are working to provide coordinated, outcomes-based high-quality medical care for patients, particularly senior patients and patients
with multiple chronic conditions, in a cost-effective manner.&nbsp; ApolloMed focuses on addressing the healthcare needs of its
patients by leveraging its integrated health management and healthcare delivery platform that includes Network Medical Management,
Inc. (an MSO), Apollo Medical Management, Inc. (an MSO), ApolloMed Hospitalists,&nbsp;APA ACO, Inc. (the Company&rsquo;s NGACO),
Allied Physicians of California IPA, a Professional Medical Corporation d.b.a Allied Pacific of California IPA (an IPA) and Apollo
Care Connect, Inc. (the Company&rsquo;s Digital Population Health Management Platform).&nbsp; For more information, please visit&nbsp;www.apollomed.net.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>This press
release contains forward-looking statements&nbsp;within the meaning of the Private Securities Litigation Reform Act of 1995, Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements
about the Company&rsquo;s acquisition strategy, integration of its acquired companies, continued growth and business outlook, ability
to deliver sustainable long-term value, ability to respond to the changing environment, operational focus and strategic growth
plans.&nbsp;Forward-looking statements reflect current views with respect to future events and financial performance and therefore
cannot be guaranteed.&nbsp;Such statements are based&nbsp;on&nbsp;the current expectations and certain assumptions of the Company's
management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results.&nbsp;Actual
results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown,
including the risk factors described from time to time in the Company's reports to the SEC, including, without limitation, the
risk factors discussed in the&nbsp;Company's Annual Report on Form 10-K filed with the SEC on&nbsp;March 18, 2019.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR MORE INFORMATION, PLEASE CONTACT<FONT STYLE="color: #4D4D4D">:</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Asher Dewhurst</B><BR>
(443) 213-0500<BR>
<U>asher.dewhurst@westwicke.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !U 5(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M88V\M%C;!)ZYSZ5SGB/2/[#UVYL Q98F&QCW'45ZC\*@H\+,5^\93NKB?B:
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M-E:L'=3,XZ%^U:X    P!VI:*F4G+=E**CL)BEHHJ1A1110 4444 )7 >./
M^H^(M:2ZLWB$8C"X<\YKT"B@#G?!.A7/A[0Q:7;(9-Y;*GBNBHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
